J Gynecol Oncol.  2011 Dec;22(4):292-294. 10.3802/jgo.2011.22.4.292.

Long-term recurrence-free survival in a patient with stage IVB uterine carcinosarcoma

• Yoon G
• Kim YS
• Kim BG
• Bae DS
• Lee JW

• KMID: 2173632
• DOI: http://doi.org/10.3802/jgo.2011.22.4.292

Abstract

Uterine carcinosarcomas are rare and highly aggressive tumors with a poor prognosis. Due to early metastasis and disease progression, it is known to be far more aggressive than matched grade 3 endometroid endometrial carcinomas. Five-year survival for stage IV is reported to be 10% and overall survival for stage IVB is expected to be very poor. The authors report one case after experiencing long-term survival (over 5 years) for stage IVB carcinosarcoma of uterus. Total abdominal hysterectomy and bilateral salpingo-oophorectomy was performed to 56 year old patient for uterine myoma. On pathology report, uterine carcinosarcoma was diagnosed and image studies were performed. With the impression of stage IVB uterine carcinosarcoma, 6 cycles of chemotherapy (ifosfamide and cisplatin) was conducted as adjuvant. Up to recently (over 5 years), she maintains good performance scale without evidence of tumor recurrence or disease progression.

Keyword

Long-term survival; Uterine carcinosarcoma

MeSH Terms

Carcinosarcoma
Disease Progression
Endometrial Neoplasms
Female
Humans
Hysterectomy
Myoma
Neoplasm Metastasis
Prognosis
Recurrence
Uterus

Figure

• 

  Fig. 1 Histologic and radiologic images of carcinosarcoma. (A) Pathologic slide for main mass (H&E, ×400). (B) Pathologic slide for ovarian metastasis (H&E, ×400). (C) Positron emission tomography image (hepatic metastasis and some of peritoneal seeding nodules).

Reference

1. Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, et al. Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol. 2008. 112:64–70.

2. Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol. 1989. 161:309–312.

3. Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2007. 25:526–531.

4. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007. 107:177–185.

5. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys. 2004. 58:786–796.